Tyme (TYME) 20 May 202020 Q4 Earnings call transcript

Good evening and welcome to the Tyme Fourth Quarter and Fiscal Year 2020 Investor Conference Call. I'd like to remind you that this call is being recorded.

I'd now like to turn the call over to Mr. Brian Gill, Corporate Communications and Investor Relations for Tyme.

Thanks Daniel and welcome everyone to our fourth quarter and fiscal year 2020 investor conference call. our to operating of the website www.tymeinc.com. reporting accessed can Tyme's release at going by Investor press financial results and be corporate The Relations section

Chief prepared Chief Priore; and Officer, and Giuseppe Officer, our Ben Operating Business our Joining Chief our Chief Financial remarks Dr. our our Michele today Steve Hoffman; Chief with Chairman me Jonathan Del and officer, Executive Taylor; Medical Officer, President Dr. are Eckard. Korfin; Officer,

making plans. during forward-looking operational risks reminder, As are cause today’s to from may financial to will be actual subject that regarding call, and differ statements a those outlook regulatory we our and These to addition in forecasted. uncertainties results product and development statements

our These be with revise we update most recent A them. speak these statements specifically to description today’s of XX-K the disclaim filed in risks date SEC. or as found can of only obligation and any to be

and I’d now Officer, turn over the Steve call like our to Chief Hoffman. Executive Chairman to

you, company, will Brian. fourth with a pivotal of that afternoon as first us for joining SM-XX results year full XXXX, for public In our thanks fiscal third-line delivered with today. pancreatic the our extraordinary trial culminating launch Thank patients cancer. evaluate Tyme and Good

sarcomas, develop metastatic, mechanism advanced as prostate, studies. better cancers, and XXXX pancreatic preclinical body to for major second study that and to growing capital pivotal cancer, highest at resources corporate to Our expand priorities for and clinical as data third-line into of initiate programs in trial, out position were Tyme breast, ensure and continue studies data present our international meetings, well clinical planning medical pivotal carry clinical trials its and hematological

We the emerging therapies. drivers position fiscal believe of this truly leadership in and multiple release that class data. value TYME-XX anticipate including metabolism-based of in We accomplishments new our our preclinical of demonstrate SM-XX XXXX, catalysts year and cancer

our and on continue to uninterrupted as pursuit committee our the endeavors. maintain and and techniques ability objectives. effect pursuit of of developed and I'd to Tyme executives Tyme take discuss responsibility moment a its to adaptations has group duties, to incorporated of like COVID-XX continue allow as well to

We have note drug to of essential third-line the because the doesn't is remotely pancreatic allow have because our of by also and and taken clinical to for patients application. is drug us It be or part in center serve like trials. been clinical important minimally product in our a sarcoma require in This sufficient that oral COVID inventoried supplies to trials cancer crisis. infusion treatment that nature we offer and can an hospital affected

has management Additionally, by adverse was historic oncologist potentially of patient small making SM-XX events, easier. amount treating the shown a

the over fiscal their more I'd expected and value to on Now, drivers you turn over like key call turn perspectives team our Michele it with I'd detail in Korfin. share fiscal in XXXX. to to to leadership XXXX like

Thank you, Steve.

launch which Precision We using our registration the also about cancer excited pancreatic the has intent. trial in pivotal launch of are truly and Promise Tyme the SM-XX study of

potential of the to options pancreatic And therapeutic where importantly, cancer, SM-XX their bring the limited. opportunity with about we patients excited to are advanced are

Tyme, I highlights and Before key touch that on we focus, our brief a development, I today, summary on opportunities. on wanted commercial to move provide to covering will science, regulatory our clinical

has strong by studying patent Tyme and/or applications which metabolism experience with a year over a of the fourth granted are our full for Fiscal as XXX metabolism-based public therapies field been in a represented of cancer more global than leader portfolio protected a or patent XXXX company. But cancer pending. CMBTs, decade

extending XXXX. manufacturing, and methods, patents beyond composition, covers broadly portfolio patent Our use

metabolism cancer a perspective, extensively developing studied with their compounds the Warburg of effect that multiple action mechanism Tyme kill cancer mechanisms a is first-in-class approach by through exploits of unique pursuing From that action. disrupting cells

Tyme cancer target current off in regimens. toxicity can this is today's that approach therapeutic believes found unnecessary broad treatment the provide without efficacy unique

into Jonathan Dr. detail our go from our will data. preclinical Eckard on insights more encouraging new

We forward patients making in moving are second-line for Ewing’s with Precision progress our in Phase enrollment high-risk are trial TYME-XX trial X clinical intent of third-line and in trials cancer, and ongoing equally PanCAN we the our Part for cancer, registration sarcoma the Panc HopES pancreatic Promise pancreatic Phase excited II II/III about trial pivotal in sarcoma. the

delivering can emphasize enough therapy in the existing through be by the oral importantly, oral market. we of environment, be administered can advantages to of patient's uncertain the the with to And of SM-XX glass delivered an therapy potentially a home, cancer the today's [ph] and An patient telemedicine doctor platforms. with cues benefits the potential water, monitored

turn let Business me over SM-XX to Chief call analysis data Jonathan Dr. Eckard, the his for preliminary of Now, and Officer our on TYME-XX. preclinical

AACR announced acceptance We pipeline presentation Thank the recently and of abstracts program, June the Meeting. you, Virtual poster Michele. at for TYME-XX for SM-XX another

meeting, at results the information. some presented While additional abstracts be the will highlights interesting

SM-XX, and These or cancer the transport, processes. SM-XX target protein survival like processes may proprietary autophagy. compound leverages functions tumor metabolism various a disrupting Regarding include CMBT investigational to production, cancer is that acid altered amino

microenvironment. the and There abstracts cellular in-vitro including SM-XX had effects agent are models. MPS cancer single could also without in-vivo impacts, components have that's on indications the SM-XX altering focus the that dynamics tumor that immune This of broader on

reported that compared SM-XX observation increases of oxygen models main reactive controls. well in significantly lines, species cancer also several abstract was cellular to reduced reported as cellular tumor in size in dose-dependent xenograft as SM-XX alterations cell The One mouse autophagy.

studied and cell's by cancers. focus as and had employed therapy increased has digestion autophagy being Autophagy Just many a cancer recycling for in target in is and mechanism currently a background, components is important of clinical trials. is an own independent the

on focus and These the immune immune-oncology other the on tumor-associated a look they presenting potential are outlines macrophages, findings to or additional during detail these AACR on and specifically upcoming we current Additionally, may TAMPs. the related Meeting. abstract impact have immune cells in alteration, research, SM-XX forward the

from SM-XX us cancer internally with future multiple to our the these aim data academic the and deepening development and optimal both on Mayo combination models in at with We to are our paths in SM-XX. inform learning Clinic. partners settings effects NYU investigation leverage We of

Moving metabolism-based cancer related is SM-XX, composition, but inter-tumoral aims leverage its another altered TYME-XX in compound to cancer TYME-XX, distinct like for susceptibilities designed it TYME-XX are to delivery. is to the that metabolism. of

it's to up that of around an tumors Solid glycolysis compared pH alteration environments from different excess lowered the metabolism, have from from lactic the tumor. physiological the acid these differences cancer of build metabolic tissue. stem normal whether byproducts the cell resulting other or Many

aimed with This membranes, acid. produced. of to permeability a the alters byproducts target cancer pathways combination steroid TYME-XX have acid steroid by they is cell a proprietary cancer combination of the the used cells. their metabolism surfactant susceptibility increasing specific toxic to is And a the

minimizing would a product the while Importantly, goal core the the effective local tumor impacts create to toxicities. normal in microenvironment, that be of systemic tissue, tissue, a in to creation TYME-XX detrimental was or

abstract, to is within AACR These And outlined mouse XX the xenograft two out preclinical that control-treated all initial continued in-vivo grow models their of responses TYME-XX in XX we this the included weeks. results. XX compared tumors mice of to tumors were encouraging had with In aggressively. mice complete treated

TYME-XX animals. toxicities local in And systemic the importantly, was there or treated no reported

safe While, radio substantial, patients that TYME-XX inter-tumoral be with not could for market also risk. we and therapy could tumors represents agent but effective surgically considered a may with be different be tumors delivery than SM-XX, only in oral resectable, in believe inter-tumoral where like a patients not the high opportunity oncology

our an of preclinical conduct additional identify potential with TYME-XX, continue parallel, identifying Advisory Medical external in And the year. goal work and setting. studies We with partners IND initial will a treatment Board path this to enabling to we

strategic this the at program clinic. will And advance TYME-XX the to into time, we most assess path

look more and detailed in the both on So, June. AACR to forward Virtual sharing we data late preclinical that Meeting TYME-XX SM-XX

to call Michele Michele? I'd regulatory now you share to our like to updates. And with turn over back

Thank patients Based a Jon. meetings on evaluating as encouraging own multiple pivotal medical clinical cancer. you, for in trial XXXX, launched therapy SM-XX data potential presented year pancreatic at third-line our with Tyme fiscal the

esteemed first Board was to that We COVID-XX extent from and to which pandemic It Advisory announced know the continue Medical will from the that had helpful the we patient We is and FDA important the had spread very trial. note in to January to not prior do impact the received our initiating enrolled. guidance society.

We all our our and have trials sites still are of clinical actively enrolling. with trials of worked closely all clinical

the We despite are proud trials we were able to challenging pandemic. keep our active

We potential our and will continue evaluate situation to monitor impact business. the the to

Expected cancer. options a the patients a and are third-line poor only prognosis. U.S. treatment for is pancreatic have very two for and Patients two third-line pancreatic in third-line over XX,XXX to There half patient survival months. seeking limited actively with cancer

a need urgency We to have for SM-XX treatment patients so of sense advance option. a who great

potential continue that We of services the patients. all address clinical supplies clinical care work continuity challenges enrolled sites ensure the closely to to available and are trial and of with to support any

do the year our full We SM-XX. of commercialization in anticipate XXXX. This brings or Part enrollment leads early XXXX end the CMBT calendar one the could potential TYME-XX us closer anticipate And data X of follow XXXX. we by step Panc candidate to of

launching the Members commercialize cancer that successful of therapies we are cancer. And to trial. U.S. and broad expertise in our disease-altering will the for SM-XX completion including multiple we into be pancreatic experience have ready market, team confident Abraxane of

and and publication we patients expect Panc and/or of presentation in TYME-XX the have the of data to part present first The final study half second study XXXX. the still on

with Action Promise the also This addition, designed and In with the working Pancreatic registration trial has the close study Precision first Network, intent. patient. initiated in partnership enrolled is Cancer

adaptive is will be first and a this studied patients in as second-line experimental cancer SM-XX monotherapy. design in the trial therapy pancreatic

I learn not you For familiar organization. are to those who about encourage you this exceptional PanCAN, with of

on be pancreatic trial. as world's therapy the in and largest advocacy first chosen examined honored It group is was the to we're SM-XX focused its that cancer second-line

can regarded trial the being the you is at conducted on around country. the institutions slide, As see highly

approximately unmet and for medical all also without There opportunity significant represents are a need XX,XXX options. good Sarcoma great diagnosed patients treatment each year stakeholders.

afflicts treatment our teenagers of adults. often one sarcoma, Ewing's young and arms,

about trial Foundation. is SM-XX Dr. partnership through Joseph trial our also We the advancing are and with passionate enrolling. Ahmed actively Chawla The

endpoint so XXXX. starting rate, primary overall we response The anticipate data in available would is becoming

solid to develop in XX already are different such types responses four both and SM-XX, has demonstrated studies, separate hematologic fortunate very to malignancies. have We clinical the which a as opportunity across tumors cancer compound

drive are large needs data options. into the treatment and limited with will advanced markets these cancers expanding where help and result, of a growing addressing patients our that As are ineffective decisions there

in our We our investments hematology. to including appropriate will expanding potentially continue into and/or prostate, CMBT trials make cancer, breast pipeline, clinical

we the what opportunities have by that accomplished very and ahead. lie encouraged are are excited We about

year fiscal Giuseppe over meetings to Now, who of Del he clinical opportunities data the on the clinical XXXX perspective therapies. growing cancer has on this the continue Priore, will his multiple to call I year data of our body to and share turn in metabolism-based medical that at Dr. will field in presented expand

Thank you, Michele.

key on ASCO promising SM-XX, our candidate including We as have with ASCO, shared GI, ESMO known and also racemetyrosine leaders across data opinion AACR. multiple clinical ESMO, international clinical venues, lead GI,

prostate now garnered at with our review you share Panc you the the and a of with enthusiasm clinical previous I'll oncologists over. of TYME-XX highlights data cancer. breast key leading I in look also that the trial will have our world metastatic cancer new

this, poor is start tumor Let's metastases, Despite locations, at for no tolerable allowed patients. by the were enrollment restrictions permissive disease the into pretreated trial. emphasize and the unprecedented heavily actively of This progressing able Important with Panc we of the ECOG a to action size, on the or pancreas mechanism these performance. the prognosis that tumor even X regimen, predicted frail, TYME-XX leverage of specificity number by start our Part to patients with criteria entered data. evidenced nearly

population On results compound FDA-guided and we had of prospective fortune invaluable months this the overall [ph] the population. two of trial, similar last the for we continues to from overall the SM-XX, X lead third-line challenges slide, by led even survival the ongoing pivotal in purported interest of to TYME-XX share in cancer Panc our result compared favorably drive half patient two patient when Part despite survival out analysis XX good pancreas our now, Mannix recall year to a and to only trial a where The cancer COVID-XX. survival was added trials, to metabolism-based our

reduction circulating who Panc, in This trended least slide survive, death. had with of circulating of X XX% tumor demonstrates greater in results the at Part in towards reduction XX% patients important TYME-XX cells a risk an tumor cell the a

as the Overall, at a tumor burden. potential reduction patients development least significant XX% important an about Tyme circulating cells of achieved tumor in pancreas overall is half advancing their This survival in of role cell prostate playing surrogate is in a since circulating cancer. and for

demonstrated the patients, stable responses that we disease cancer. was observed TYME-XX matter death. at X in Part X response. Part XX% are valuable not also rare and in Furthermore, all learned reduction Panc XX% clinical our partial study, of rate risk the results these a year, benefit in Last including patients risk advanced in because or

Our goal frail additional safety important develop with to is a to medicines prognosis profile. deliver and When poor extremely It's better patients working with advanced extremely receive typically not are disease. tolerable to and to safer with deliver therapy groups any able therapy. cancer

potentially two related report impressive across well-tolerated Part data reporting a study, SM-XX cures. XX safety Remarkably, events, patients X therapy. X% SM-XX we continue The was of variety to TYME-XX adverse for observe to and serious of least only or of at Panc

tumors profile patients. separate representing encouraging hematologic different approximately tumor solid across if including SM-XX XX safety in malignancies aggregate, an four types, XXX has and In demonstrated studies,

is important Panc to is control pivotal still that randomized the albeit TYME-XX note trial. X X Part Part now study It two ongoing,

to X Part continue forward We patients presenting of follow-up data and/or near end the the publishing to XXXX. final look and

On the of treated for final In Tyme setting to the we cancer. move of major on institutions SM-XX key captured thought recurrent to leaders being when prostate patients cancer, attention, prostate prostate our data the cancer. this slide, shared II Phase with we advanced

results were Six are of typical free patients meaningful months any data of patients XXX% These progression, side of because hormone-related progression. and radiographic SM-XX effects. XX% demonstrated of clinical important remain free metastatic without

study, the need current change with postpone patients biochemically SM-XX paradigm the recurrent hormone randomized could prostate for confirmed for a cancer. and in therapy If treatment

University Tyme As our is and Medicine. California Memorial we number earlier, investigators Based proven San including documented. in these and In Sloan discussed working of leadership and of of Einstein clinical Phase prostate prostate cancer, study, we playing leading are the the a Albert institution circulating role cells. development tumor a Francisco, on if findings, with circulating in the II Kettering, was the College tumor cell

outside continue prospective leveraging to trials We pursue funding. opportunities to results, for SM-XX confirm

Moreover, of and we biotech. clinical understand scientific are that heartbeat the any data

in prostate As calendar data such, we reviewed this final share our the II half Phase publication the study a peer year. from cancer in to intend second recurrent of

benefit with based experience, a There trial There overall have hormone no we summary adverse with previously or our On in approximately safety this favorable The experience cancer. compassionate related and breast clinical metastatic events. experience breast presented rate XX unanticipated These or response a treatment, of our were first patients the on status, profile. gathered with was slide, was XX%. indication cancer. see a SM-XX of site. the use human no Through resistance prior of we drug receptor sample metastatic patients

better healthcare are for approach results providers cancer looking with for potentially clinical These encouraging are breast who patients and a their metastatic new a and option.

treatment as leaders Based and are key on a development opinion cancer. SM-XX support the potential of advanced metastatic and breast these from their for patients for opportunities exploring we findings strong institutions, with

Ben for operating our and comments turn his results. call financial Now, to on let me over Taylor the

you, Thank Giuseppe.

March had in approximately As fourth compared ended we to the quarter quarter. XXst in $XX.X $XX.X of cash million and the third XXXX, million equivalents

includes Our million share. January at quarter cash investment fourth from by Eagle strategic $X balance $XX per the Pharmaceuticals

million $X.X fourth quarter, to compared in Our operational for increase than fiscal timing XXXX rather over million primarily was operational to of of -- for prior the previous was the quarter quarter activities. quarter The $X.X for and cash burn million fourth year difference to payments attributable the the of $X.X quarter rate XXXX. fiscal the

burn recent The and for quarter the fiscal both trials previous million with year. generally prior the guidance was ongoing for predominantly $XX.X and for their burn costs $XX.X compared with consistent most full the was clinical reflected XXXX million the year cash in rates Operational year to our associated SM-XX.

expected cash clinical year million active SM-XX Based and pre-clinical our quarterly Tyme application primarily $X the its anticipates on burn for potential with $X operational FDA, per new for that is preparation approximately XXXX. million a quarter their to trials average activity, fiscal to drug

to shown strategic cash As support the inflows markets expect long-term goals our than we lower private, quarterly opportunities in channels, for cash including public, cash across objectives. previous to the generally and actual net burn multiple on be has been based and anticipated burn operational quarters,

preclinical equivalents cancers, that as March our with studies. as additional continue carry to is of capital our trials adequate the cash We mechanistic and cancer, XXXX, anticipated believe programs trials our pivotal together to advanced hematological breast as XXst, sarcoma, in access are in in well potential pancreatic

It know trials. is for existing clinical uncertainty SM-XX in Tyme pandemic. supply studies continue of continuity by to company the ensure SM-XX any our for important COVID during future to and components The ability confident the fourth to caused fiscal MTS supply significantly to and during chain potential its of increased that quarter XXXX inventory ongoing its remains

of of Further, all associated any the have Today, initiating period. we warrants conversion to that months the for of also potential shares bans agreement announced our warrants. million out with warrant sales that all during agreed X restricts leak six a holders outstanding short-sells and XXXX

A and at and warrants to $X.XX of to other strike converting remaining a majority X.X warrants being to governance ratio common price X. the X.X common are words are with exchanged removes the previous provisions The shares price warrants X.X shares. warrant the the million new for from of million million X.XXXX anti-dilution, warrants. protection, In

please detailed more of warrant was see revised X-K the closed. today filed market review agreements, that a For after

Hoffman call for I'll time, to this closing Steve turn back comments. At the over

exceeded met and corporate that can goals beyond. XXXX XXXX goal you, to continue proudly say Ben. Tyme for plans team Thank performance outstanding have we our all that and or for

higher for with priority metabolism-based cancer third-line candidates trial no Panc is oral evaluating to pivotal than a potential pancreatic cancer. SM-XX our have that TYME-XX patients late as we treatment fiscal For execute our XXXX, successfully

pancreatic with there metabolism. FDA approved need pancreatic recommendations no actively patients therapy. guideline for and patients believe no can for in that we fill therapies third-line seeking of field approach new cancer cancer that the XX,XXX those advances the are unmet treatment, latest active oncology applies a So, currently We with

source, we're our By therapy at its to of in patients targeting of hope a forward the We're of outcomes cancer deliver new about SM-XX improved potential this the promising excited we pancreatic results and mechanisms patients. first-in-class for as study. the to for approach pivotal looking significantly

in cancer their aspire providers, and healthcare Tyme of advancing As role for field as where we hope Tyme, leading patients, resource a a serve we better, medicines. to for valuable pouring the -- at play advocates safer can deserve metabolism,

and prepared fiscal are our We maximize to XXXX our stakeholders. for all ready execute year strategy in to our of value and proposition

Tyme. for you concludes Thank session. now a operator interest remarks. That my the would to to I over turn for the in prepared your call like question-and-answer

Instructions] [Operator

And our H.C. from question Lee Wainwright. comes Sean first with

Your line is open. now

pandemic. just and remarks, far clinical the I guys afternoon my the from ongoing questions. in question on mentioned for study Good Promise study? the know so that have first you for studies refer well? minimally does the that COVID-XX have how thanks or taking Panc wondering, is been My Precision effective. to do impact study visibility the into XX I was that much And prepared as you the

is Thank for Korfin. joining thank this the for question. us and Sean, so Michele you Hi much you

ongoing trials for study. our which in all were COVID-XX, specifically terms our to prepared TYME-XX about is regard pivotal sarcoma. Panc, in intended third-line talk cancer I'll So, and clinical the of pancreatic of remarks SM-XX

minimal in before impact such is most prepared say hit. we know, minimal You pandemic. Tyme, up seen XX a Steve sites But I his we and hit. impact. We've the seen challenging since pandemic our and study fortunately I pandemic remarks, have will This indicated in for running had as the reiterated,

great This cancer is a situation is advanced where need. unmet a pancreatic such

throughout Our trial pandemic. the active has stayed

to the sites need to excited center them if to with sense benefit trial oral any have an go treatment in work partner not the clinical And challenges. to the to of also the with continue administration. to for therapy, the address We challenges future to patient does that do we're continue arise our and

Good.

enrollment patient also that. it you take expected; is any to that I seen along going slowdowns haven't So, as

Yes.

of either XXXX. I remarks by guided slight today But the of enrollment that you, Sean. end of update by I had we enrollment Steve beginning in the to-date, been saying in and We previously XXXX prepared said we XXXX. full the as we or terms the thank give minimal end has anticipated the did full impact impact enrollment. terms our of on the in anticipate of So,

Great. thank second and the My That's for cancer you good color. to the question prostate hear is program. additional on

be plans final So, with prostate company well? in year, data SM-XX this the study to because into cancer from published advance as II a the Phase to pivotal the the later

question. excellent So,

the then of in will the would terms start he I'll anything by milestone be from me Giuseppe been us had prostate to, presented ASMO. The Phase data the next manuscript I'll publication Phase and Giuseppe actually II like Let for so key to if that add II at the study. ask on of prostate

the ASMO, really And if you analysis. on from some on will Giuseppe in prostate poster that final note leaders very with participated thought well-recognized

for to future continued terms leaders might have potential in SM-XX what with we of be So engage thought in prostate. the

to-date a to an expansion. indicated as study have our that may but area we look that remarks, is during We discussed prepared or not registration initiated further for we one,

let prostate. additional on me so Dr. any for Priore to Del turn And now comments

Hi.

enthusiasm is posters previous presentation that right trial. on answers in only this emphasize I and and our Michele reflected the think was on collaborators

forward So, future. do to that the look we in

is My TYME-XX. helpful. on the that Great, was last question

So, with that AACR, has a also how look first AACR the the at sorry, performs. function

into will for the And the advancing questions. potential so Thanks clinic? be what I'm my timeline for taking wondering, again

Sean, Hello, Eckard. this Jon is

and drug, best making figure work, to And into what now support preclinical partners course, then optimally forward findings. strategically the before both our finance to the on goal But develop the the out to advisors based a moving and optimally exactly such to to all clinic. to move external drug precisely try develop clinic, on decision of to on to So, where way how that to the clinic. preclinical our would is get needed assess internal and the be identify official right with do more

certainly my all we over the as remarks once would more about the towards some advancing have into will make the what of identifying we time, more next the And -- able at said it steps in the I course be clinic. be we to be that announcements the steps. in some should year, right those So, prepared clarity,

I see. Thanks.

Thank you. [Operator Instructions]

question with Kevin DeGeeter from Oppenheimer. comes next our And

open. Your now line is

And Hey, the thanks you help us all try the to doing better for pancreatic understand mechanism. thanks that Jon understand you've And we've curious you and your how that that maybe interesting been call. process I population, full of Could little mechanism back think to which with thought for patient update sort the the here pull circle in regard a action. empirically? some to have of work of seen on on work just now about informs the we activity been patients?

Yes, Kevin. very thank much you

process to there's more prepared autophagy, than in AACR, important not abstract how to obviously, cancer, submitted a patient. remarks out of things of cancer the what and highlighted bunch in in -- in survives was is so very a but there's so in coming effect pancreatic to the that survival, of performs the be the was going which But only aspects data that the one whole So, at was other December. of

multiple mechanisms, aspects think times be working. I be each said to that of and SM-XX how there of call, in seems to so, SM-XX this we've that well as it which -- appears the as And several

also far, but so And only to what so found deeper we in. digging look we forward not explaining

other in to where also about this are more but those this diseases pancreas, only help understanding specific in will information again, known And biological important. not be us processes

your would time. dig going that I certainly So, best please to to lot share there. be the to stay to guess, And in AACR, be tuned of be able there's to answer after interesting probably a deeper question information

kind of have do maybe studies direct such that's thought compounds until in compounds perhaps sets here a looks consistent of any just optimal with the of follow-up mean, what other of as the it hypothesis as test need to And if on some data have purport some on processes prior sort at those not of are the the hydroxychloroquine I terms other it. help to metastatic a to what applicable that Panc. prior out necessarily wait you or of this seen, think may with things the those trees there of we've mixed this of AACR, the prior Got but and that kind results after impact some promising to activity of a read sort shouldn't a informed of experiences, study might SM-XX? you be is in mechanism that top one

The there only several like of autophagy and thing aspects compounds ways. is in I'll certain say that impacted are hydroxychloroquine

And so better autophagy. ways worse there are ways to or impact probably

have happen so were for drugs those that to found to do were and So, that studied hence been it.

But are the there as MEK other in such different example. sort ways drugs alter of for who inhibitors

other autophagy So, about how impacts not of be I think to approaches similar the only to how important. they that additional clarity what but would come pass and they are differ

focus study an the remains people again, known of still cancers. days It different a it's process important for for be of still certainly because autophagy. early to So, many

autophagy. and So, be other but targeting again, not to learned ours, approaches more only about

the in for That's data later additional super helpful the Thank forward much context. information. Thanks to June. you. so Look

you. Thank

[Operator you. Instructions] Thank

this turn at the call Gill like any questions further to Brian now to over closing would back any time. remarks. showing not I'm I for

Daniel. you, Thank

interest exciting will team you milestones. your the opportunities our thank know available pilots everybody leadership support Our any are another for be if discussions. wanted year just to be keep XXXX Tyme. let again after in call multiple we of that to all you fiscal And certainly for on with developments. We'll there in promises And follow-up current I and

Ladies for call. and gentlemen, conference today's concludes participating. you Thank this

You may now disconnect.